Physician profile
Michael Cannon
NPI 1215925599
$145,270.97
in general payments reported to CMS, 2019-2025
41 companies · $25K in 2025
The $25K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,488 · 2020: $15K · 2021: $20K · 2022: $15K · 2023: $37K · 2024: $26K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Travel and Lodging: $11K · Food and Beverage: $9,962 · Consulting Fee: $3,680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,650.00 |
| Travel and Lodging | $11,006.05 |
| Food and Beverage | $9,962.28 |
| Consulting Fee | $3,680.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $94,271.02 | 2019-2025 | Nucala, Benlysta |
| Pfizer INC. | $31,981.54 | 2019-2025 | |
| Amgen INC. | $4,293.70 | 2019-2025 | Krystexxa, Evenity, Tavneos |
| Janssen Biotech, INC. | $3,012.83 | 2019-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $2,273.83 | 2019-2025 | Rinvoq |
| Genzyme Corporation | $1,752.31 | 2020-2025 | |
| Lilly USA, LLC | $1,169.74 | 2019-2025 | Taltz, Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $1,014.19 | 2019-2025 | |
| Ucb, INC. | $945.37 | 2019-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $758.51 | 2019-2023 | Krystexxa |
| Radius Health, INC. | $486.96 | 2019-2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $408.90 | 2021-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $330.85 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals Lp | $296.89 | 2022-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.14 | 2020-2025 | Ofev, Spevigo |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $273.10 | 2020-2025 | Acthar |
| Genentech USA, INC. | $210.78 | 2019-2024 | Actemra |
| Organon LLC | $177.48 | 2022-2025 | Hadlima, Renflexis |
| Celgene Corporation | $160.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $138.90 | 2020-2025 | Strensiq |
| Ani Pharmaceuticals, INC. | $136.41 | 2024-2025 | Purified Cortrophin Gel |
| Sobi, INC | $127.76 | 2023-2025 | |
| Bioventus LLC | $95.35 | 2021-2024 | Durolane, Durolane |
| Mallinckrodt Enterprises LLC | $79.69 | 2019 | |
| Sandoz INC. | $72.49 | 2023-2025 | Hyrimoz |
| Octapharma USA, INC. | $61.77 | 2025 | Octagam Immune Globulin (Human) |
| Tersera Therapeutics LLC | $59.55 | 2025 | Quzyttir |
| Pharming Healthcare, INC. | $57.77 | 2022-2023 | Ruconest |
| Fidia Pharma USA INC. | $54.52 | 2019-2023 | Hymovis |
| Kyowa Kirin, INC. | $44.56 | 2024-2025 | Crysvita |
| Depuy Synthes Sales INC. | $42.27 | 2025 | Orthovisc |
| Regeneron Healthcare Solutions, INC. | $27.36 | 2019 | |
| Fresenius Kabi USA, LLC | $26.95 | 2023 | Idacio |
| Pacira Therapeutics, INC. | $24.10 | 2019 | |
| Invivyd INC | $23.30 | 2025 | Pemgarda |
| Tonix Medicines, INC. | $22.93 | 2025 | Tonmya |
| Seqirus USA INC | $21.50 | 2025 | Flucelvax, Fluad |
| Kiniksa Pharmaceuticals, Ltd. | $15.00 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.35 | 2019 | |
| Hikma Pharmaceuticals USA | $12.15 | 2019 | |
| Sebela Pharmaceuticals INC. | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.